Tag Archives: tirzepatide
Tirzepatide in HS: Signals From a TriNetX Cohort
Tirzepatide or GLP-1RA exposure was associated with different two-year outcomes in a matched hidradenitis suppurativa cohort.
Tirzepatide: 22,104 Matched Bariatric-Surgery Patients
Tirzepatide or GLP-1RA use before bariatric surgery was associated with fewer 90-day cardiorenal events in 22,104 matched patients.
Tirzepatide: 415 Matched Knee-Arthroplasty Pairs
Tirzepatide and semaglutide showed similar 90- and 180-day postoperative outcomes in 415 matched pairs undergoing knee arthroplasty.
Tirzepatide vs Semaglutide: 8,176 Asthma Pairs
Tirzepatide and semaglutide had similar recorded asthma-exacerbation risk in 8,176 matched pairs, while SABA use differed modestly.
GLP-1 and Lean Mass: 60 Studies, 1.25m People
GLP-1 evidence from 60 studies found lower lean mass, but no significant bone or joint effect and low certainty for muscle implications.
Tirzepatide and Cold: No Added Loss in Mice
Tirzepatide and intermittent cold exposure improved separate measures in obese mice, but the combination did not add weight loss.
Tirzepatide in IBD: 3,042 Matched Pairs
Tirzepatide in IBD was associated with fewer IV steroid events in 3,042 matched pairs, but the retrospective design cannot establish cause.
Tirzepatide in HFpEF: LV Mass Down 12.4 g at 6 Months
The International Journal of Cardiology published a prospective cohort study online on 8 September 2026 by Karanxha, Guni, Xhabija, Ded...
Tirzepatide 15 mg: 1.60 kg of Fat-Free Mass Lost
Tirzepatide 15 mg cut fat-free mass by 1.60 kg in a meta-analysis of 19 trials, where laboratory screening found risk the trial reports missed.
Tirzepatide and Semaglutide: 15-20% in a New Review
Tirzepatide and semaglutide give 15 to 20 percent mean weight loss over 12 to 18 months, a new narrative review reports, with wider gains.